California-based late-stage biotech company Alume Biosciences announced on Friday that it has named Rick Gonzalez as its new chief commercial officer.

Gonzalez has more than three decades of experience in the pharmaceutical industry, serving in senior roles that involved significant global responsibilities. He led the development and implementation of globalisation and commercialisation strategies across Europe, Asia, the Middle East and Latin America at Spectrum Pharmaceuticals. He has expertise in specialty markets including Surgery, HIV/AIDS, Hematology and Oncology, with a comprehensive background in sales, marketing, operations, distribution, managed markets and government affairs. Gonzalez has also worked in key roles at companies such as Abraxis Oncology, Genzyme, Ligand Pharmaceuticals, Roche Laboratories and GlaxoSmithKline.

Dr Quyen Nguyen, Alume Biosciences CEO, said: "Alume is thrilled to welcome Rick Gonzalez as our new chief commercial officer. Rick's profound global commercial, operational and leadership experience, particularly in surgery, biotechnology, radiopharmaceuticals and medical devices, is directly aligned with our strategic objectives. His proven track record in product commercialisation will be instrumental as we advance ALM-488 towards a successful market introduction."